
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : ScaleReady
Deal Size : $0.1 million
Deal Type : Funding
OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements
Details : The grant will support OverT Bio’s ongoing development efforts leading to next generation cell therapies for solid tumors, based on innovative data-driven discovery platforms OverTarget and OverTCR.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 22, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : ScaleReady
Deal Size : $0.1 million
Deal Type : Funding

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : ARTIS Ventures
Deal Size : $16.0 million
Deal Type : Financing
OverT Bio Raises $16M for Immune Cell Reprogramming to Develop Next-Gen Therapies
Details : The funding will be used in expanding discovery platforms focused on addressing the primary barriers for cell therapy, leading to durable and curative treatments for advanced solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 06, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : ARTIS Ventures
Deal Size : $16.0 million
Deal Type : Financing
